Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Operations: 2009-2024

Historic Cash from Operations for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$23.1 million.

  • Lineage Cell Therapeutics' Cash from Operations rose 37.52% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.4 million, marking a year-over-year increase of 10.45%. This contributed to the annual value of -$23.1 million for FY2024, which is 19.16% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Cash from Operations stood at -$23.1 million for FY2024, which was up 19.16% from -$28.6 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Cash from Operations registered a high of $1.1 million during FY2022, and its lowest value of -$28.6 million during FY2023.
  • Moreover, its 3-year median value for Cash from Operations was -$23.1 million (2024), whereas its average is -$16.9 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 104.49% in 2022, then plummeted by 2,797.45% in 2023.
  • Lineage Cell Therapeutics' Cash from Operations (Yearly) stood at -$19.8 million in 2020, then decreased by 19.28% to -$23.6 million in 2021, then spiked by 104.49% to $1.1 million in 2022, then tumbled by 2,797.45% to -$28.6 million in 2023, then increased by 19.16% to -$23.1 million in 2024.